20. RESULTS OF HELICOBACTER PYLORI TREATMENT ACCORDING TO ANTIBIOTIC SUSCEPTIBILITY IN CHILDREN WITH GASTRITIS AND PEPTIC ULCERS AT CHILDREN'S HOSPITAL 2
Main Article Content
Abstract
Objective: The aim of this study was to determine the antibiotic resistance rates of H. pylori and the eradication outcomes of first-line treatment regimens based on susceptibility testing in children at Children’s Hospital 2 from January to December 2024.
Methods: A retrospective descriptive case series study.
Results: From January to December 2024, 136 patients were included. The mean age was 9,6 ± 2,4 years, with the 6–10 years age group being the largest (46,3%). Females accounted for 53%. Family history of H. pylori infection was reported in 57.4%, indicating familial transmission risk. Nutritional status showed 53% normal, 29.4% underweight and 17,6% overweight, obese. Abdominal pain was the predominant symptom (93.4%). Upper gastrointestinal endoscopy revealed inflammatory lesions in 81% of cases and ulcerative lesions in 26,5%. Resistance rates were high for clarithromycin (100%), amoxicillin (77.9%) and metronidazole (69.8%), while resistance to levofloxacin and tetracycline was lower (31,6% and 2,2%, respectively). The overall eradication rate was 63.9%, about 77,9% of patients showed symptom improvement after treatment. There was a significant association between symptom improvement and successful eradication (OR = 5.31; p < 0,001).
Conclusion: This study showed a relatively high resistance rate of H. pylori to clarithromycin and amoxicillin. Therefore, choosing antibiotics based on susceptibility testing and personalizing treatment is important to improve eradication rates.
Article Details
References
[2] Tăng Lê Châu Ngọc. (2018). "Đặc điểm đề kháng kháng sinh và đáp ứng điều trị trên trẻ viêm dạ dày do Helicobacter pylori"; Luận văn chuyên khoa II, Trường Đại học Y Dược TP. Hồ Chí Minh.
[3] Nguyen TC, Le GKN, Pham DTH, et al. (2023). Antibiotic resistance and heteroresistance in Helicobacter pylori isolates from symptomatic Vietnamese children: A prospective multicenter study. Helicobacter; 28(5):13009.
[4] Marshall BJ, Warren JR. (1984). "Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration". Lancet; 1 (8390):1311-5.
[5] Miao, R., Chen, J., Gao, S. et al. (2024). A randomised controlled clinical study of standard triple therapy, bismuth-based quadruple therapy and sequential therapy for Helicobacter pyloriinfection in children. BMC Pediatr; 24, 543.
[6] Nyssen OP, Bordin D, Tepes B (2021). On behalf of the Hp-EuReg Investigators, et al European Registry on Helicobacter pylorimanagement (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients Gut ;70:40-54.
[7] Thuy LLT, Nguyen LT, Vu HA, Nguyen NA, Nguyen TA (2024). Effect of MDR1 C3435T and CYP2C19 genetic polymorphisms on the outcome of Helicobacter pylori eradication treatment in children with gastritis and peptic ulcer, Vietnam. BMC Pediatr; 19; 24(1):464.
[8] Zhou D, Wang W, Gu L, Han M, Hao W, Huang J, Lin Q, Wang Y (2024). Helicobacter pylori antibiotic resistance profile in Chinese children with upper gastrointestinal symptoms and a literature review for developing personalized eradicating strategies. Front Pharmacol; 3(15):1392787.